Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNG1005 vs investigator’s choice chemotherapy in HER2-negative breast cancer with newly diagnosed leptomeningeal metastases
CTR20221859Phase 3Active
- Sponsor
- Xinnuokang Pharmaceutical Technology
- Start
- Aug 2022
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of paclitaxel trevatide in breast cancer and Carcinomatous Meningitis (CM) (2 arms), sponsored by Xinnuokang Pharmaceutical Technology. Started Aug 2022; status: active.
02
Drugs
paclitaxel trevatide
03
Conditions
breast cancerCarcinomatous Meningitis (CM)
Beyond the preview
Go deeper on CTR20221859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221859.